missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Opucolimab Recombinant Monoclonal Antibody
Recombinant Monoclonal Antibody
Brand: Invitrogen™ MA559644
This item is not returnable.
View return policy
Description
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Opucolimab, also known as HLX20, is a recombinant human monoclonal antibody that targets the programmed death-ligand 1 (PD-L1), also referred to as CD274 or B7-H1. CD274 is a gene encoding a protein critical for immune checkpoint regulation. Located on chromosome 9, this protein is expressed on the surface of various cell types, including tumor cells, immune cells, and normal tissues. PD-L1 interacts with the PD-1 receptor on T cells to modulate immune responses, particularly by promoting self-tolerance and preventing autoimmunity. In the context of cancer, aberrant expression of CD274 allows tumor cells to evade immune surveillance, leading to immune escape. This mechanism has made CD274 a significant target for cancer immunotherapies, particularly immune checkpoint inhibitors such as pembrolizumab and nivolumab, which block the PD-1/PD-L1 interaction to restore anti-tumor immunity. Research on CD274 continues to reveal its role in various malignancies and its potential as a prognostic and therapeutic biomarker.
Specifications
| Opucolimab Humanized | |
| Recombinant Monoclonal | |
| Unconjugated | |
| Human | |
| 1 mg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Lyophilized |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| 1 mg/mL | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Protein A | |
| RUO | |
| Human | |
| Antibody | |
| IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction